Brokerages expect American Renal Associates Holdings Inc (NYSE:ARA) to post $216.70 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for American Renal Associates’ earnings. The highest sales estimate is $219.00 million and the lowest is $214.40 million. American Renal Associates posted sales of $187.71 million in the same quarter last year, which suggests a positive year over year growth rate of 15.4%. The firm is scheduled to report its next earnings results on Tuesday, November 13th.
According to Zacks, analysts expect that American Renal Associates will report full year sales of $849.50 million for the current year, with estimates ranging from $846.00 million to $853.00 million. For the next year, analysts anticipate that the business will report sales of $932.50 million, with estimates ranging from $925.00 million to $940.00 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover American Renal Associates.
American Renal Associates (NYSE:ARA) last issued its quarterly earnings data on Tuesday, August 7th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.03. The company had revenue of $217.18 million during the quarter, compared to analyst estimates of $203.70 million. American Renal Associates had a positive return on equity of 19.60% and a negative net margin of 1.11%.
Several research analysts recently weighed in on the company. Leerink Swann upgraded American Renal Associates from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $22.00 to $26.00 in a research report on Thursday, August 23rd. Zacks Investment Research upgraded American Renal Associates from a “sell” rating to a “hold” rating in a research report on Thursday, August 9th. Bank of America lowered their price objective on American Renal Associates from $25.00 to $21.00 and set a “buy” rating for the company in a research report on Tuesday, July 10th. SunTrust Banks reiterated a “buy” rating and issued a $25.00 price objective on shares of American Renal Associates in a research report on Thursday, August 9th. Finally, Goldman Sachs Group assumed coverage on American Renal Associates in a research report on Thursday, July 19th. They issued a “neutral” rating and a $16.00 price objective for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $22.60.
A number of institutional investors have recently modified their holdings of ARA. JPMorgan Chase & Co. grew its position in American Renal Associates by 34.0% in the first quarter. JPMorgan Chase & Co. now owns 754,951 shares of the company’s stock worth $14,230,000 after acquiring an additional 191,589 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of American Renal Associates by 96.9% during the first quarter. Dimensional Fund Advisors LP now owns 255,166 shares of the company’s stock worth $4,810,000 after buying an additional 125,561 shares during the period. A.R.T. Advisors LLC purchased a new position in shares of American Renal Associates during the first quarter worth $354,000. Barclays PLC boosted its position in shares of American Renal Associates by 23.9% during the first quarter. Barclays PLC now owns 52,295 shares of the company’s stock worth $986,000 after buying an additional 10,093 shares during the period. Finally, Element Capital Management LLC purchased a new position in shares of American Renal Associates during the first quarter worth $263,000. Institutional investors own 93.25% of the company’s stock.
American Renal Associates stock traded down $0.54 during mid-day trading on Friday, hitting $17.73. The company’s stock had a trading volume of 136,200 shares, compared to its average volume of 161,558. The firm has a market capitalization of $579.86 million, a price-to-earnings ratio of 29.93, a PEG ratio of 3.16 and a beta of 2.51. American Renal Associates has a 1 year low of $9.91 and a 1 year high of $24.07. The company has a debt-to-equity ratio of 5.30, a quick ratio of 1.04 and a current ratio of 1.07.
About American Renal Associates
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
Featured Article: How Important is Technical Analysis of Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.